Compositions and pharmaceutical forms for the treatment and prevention of coronavirus, which contain in its formulation non-hydrolyzed collagen as a surfactant with degreasing properties and natural active ingredients in the form of hydrolyzed powders of aqueous extracts of Dandelion (Taraxacum officinale), Anamu (Petiveria Alliacea), Epazote (Dysphania ambrosioides), oregano (Origanum vulgare), star anise (Lllicium verun) together with preservatives, as well as the obtaining and preparation procedures associated with the development of the different compositions and pharmaceutical forms.

A mini-tablets in capsule oral dosage form comprising a dose of atorvastatin. Also disclosed are methods of preparing the dosage form and methods of treating a condition, disease or disorder that is therapeutically responsive to atorvastatin.

A pharmaceutical formulation contains the following components in part by weight: (a) 1 part of the compound represented by Formula (I), ##STR00001## (b) 16 to 600 parts of a meltable and dispersible carrier comprising poloxamer and polyethylene glycol in a poloxamer-to-polyethylene glycol weight ratio of 1-0.5 to 1:27, and (c) 0.2 to 100 parts of a non-volatile weak acid. The pharmaceutical formulation helps to improve the in vitro dissolution of the compound of Formula (I).

The present disclosure relates to a composition for improving sleep quality, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof. The composition for improving sleep quality may improve the sleep quality by increasing melatonin secretion. In addition, in another aspect, the present disclosure provides a composition for alleviating stress, including γ-aminobutyric acid (GABA) or a salt, hydrate or solvate thereof; and at least one of arginine, niacin, and salts, hydrates and solvates thereof.

Nutraceuticals Composition A (metabolic capacity enhancing compositions) comprises extraction or powder from White Kidney Bean, Green Tea, Green Coffee Bean, Garcinia Cambogia, Gymnema Sylvestre, L-Carnitine, Guarana, Ginger Root, Dandelion Root, Capsicum Cayenne, Licorice Root, Ascorbic Acid, d-Calcium Pantothenate, Pyridoxine HCl, Potassium Chloride, Magnesium Carbonate, and Chromium Yeast. Nutraceuticals Composition B (immunity capacity enhancing compositions) comprises extraction or powder from Grape Seed, Ginseng, Garlic, Rosehips, Green tea (Decaf), Astragalus, Beta Glucan Yeast, Reishi, Shitake, Maitake, Agricus blazei, Turkey Tail, Cordyceps, and Coenzyme CoQ10. The methods to make a synergistic Composition A and Composition B are formulated and are capable to provide a bioavailable dietary supplement and phytonutrients that can help modulate metabolism and enhance the human immune system. The supplementation, consumption, of these nutraceutical formulas have preventive and therapeutic roles for chronic diseases, and thus provide anti-aging effects.

Disclosed are compositions, devices, and methods to prevent and recover from detrimental effects of alcohol consumption, including significant undesirable symptoms of a hangover consciously felt by the alcohol consumer, as well as those that may not be consciously experienced. The present technology comprehensively targets multiple negative effects of hangovers. In one aspect, a composition includes dihydromyricetin (DHM); and N-acetyl cysteine (NAC). The composition may further include Prickly Pear Extract, Milk Thistle, Ginger Root, Vitamins B, C, and E, electrolytes, and/or sugars.

The invention provides a delayed release dosage form and a bolus configured for administration to an animal, wherein said dosage form and said bolus is configured to release a hydrophobic substance to the animal over a period of time. Preferably the hydrophobic substance is a haloform. Also provided is the use of the delayed release dosage form or bolus of the invention to reduce methane production in a ruminant animal. Also provided is the method of manufacturing a bolus of the invention.

Provided herein are lipidic furan, pyrrole, and thiophene compounds, compositions, and methods using such compounds and compositions for the treatment of atrophic vaginitis. Specifically, the invention includes administering an effective amount of a compound of Formula I, I′, or I″, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from atrophic vaginitis.

The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies.

This disclosure provides nicotine-loaded microcapsules for use in treating or preventing nicotine dependence, or a withdrawal symptom thereof, in a subject in need thereof. The disclosure also provides pharmaceutical compositions and pharmaceutical formulations comprising nicotine-loaded microcapsules. The disclosure also provides methods of making nicotine-loaded microcapsules.